Introduction: Inhaled beta2-agonists are important therapeutic agents for the treatment of exercise-induced asthma in athletes but are restricted by international antidoping regulations.
Purpose: To investigate whether 18 mug of inhaled formoterol affects endurance performance during running at high altitudes until exhaustion among 20 nonasthmatic male athletes aged 21-35 yr.
Methods: : In a randomized, double-blind, placebo-controlled crossover study, the athletes performed one screening test and two similar performance tests. Each performance test consisted of 20 min of warm-up and a running test until exhaustion, which lasted 210-300 s in hypobaric conditions equal to 2000 m above sea level. Maximal oxygen consumption (VO2max) and peak ventilation (VEpeak) were measured during running, and pulmonary function was measured before and after exercise. The screening test was used to determine running speed on days 2 and 3, with inhaled formoterol or placebo in a randomized manner before exercise. VO2, VE, arterial oxyhemoglobin saturation (SPO2), and heart rate (HR) were measured during exercise, and maximum plasma lactate concentration was measured after exercise.
Results: Inhaled formoterol did not improve running time to exhaustion, VO2, VE, SPO2, or HR (P > 0.05) in hypobaric conditions compared with placebo, although formoterol significantly improved lung function (FEV1 and FEF50) 15 and 30 min before exercise and 3, 6, 10, and 15 min after exercise.
Conclusions: Inhaled formoterol did not improve endurance performance in healthy nonasthmatic athletes at hypobaric conditions equal to 2000 m above sea level. Inhaled formoterol can thus be used by asthmatic athletes in sports under extreme conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1249/01.mss.0000233801.46906.9b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database.
Front Pharmacol
January 2025
Respiratory Department, Xiyuan Hospital of Chinese Academy of Chinese Medical Sciences, Beijing, China.
Objective: Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs) associated with Budesonide/Glycopyrronium/Formoterol Fumarate (BUD/GLY/FOR) and Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Methods: This is a cross-sectional study.
Regular versus as-needed treatments for mild asthma in children, adolescents, and adults: a systematic review and network meta-analysis.
BMC Med
January 2025
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
Background: Inhaled corticosteroids (ICS) are recommended treatment for mild asthma. We aimed to update the evidence on the efficacy and safety of ICS-containing regimens, leukotriene receptor antagonists (LTRA), and tiotropium relative to as-needed (AN) short-acting β2-agonists (SABA) in children (aged 6-11 years) and adolescents/adults.
Methods: A systematic review of randomized controlled trials (RCTs) of regular and AN treatment for mild asthma was conducted (CRD42022352384).
Introduction: Triple inhaled therapy (TT) in one device has been shown in clinical trials to reduce exacerbations and in some cases mortality compared to dual inhaled therapy (DT) in one device in the population of moderate to very severe COPD patients and previous exacerbations. This evidence must be contrasted in real-world conditions.
Patients And Methods: Non-intervention retrospective cohort study comparing the incidence of moderate and severe exacerbations in COPD patients treated with TT (formoterol, glycopyrrolate and budesonide, 5mcg/72mcg/320mcg, n=112) and DT (LAMA/LABA/ or LABA/inhaled glucocorticoid, n=107) for 26 weeks under clinical practice conditions.
A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs.
ACS Pharmacol Transl Sci
January 2025
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), Silver Spring, Maryland 20993, United States.
Current in vitro cell-based methods, relying on single cell types, have structural and functional limitations in determining lung drug permeability, which is a contributing factor affecting both local and systemic drug levels. To address this issue, we investigated a 3D human lung airway model generated using a cell culture insert, wherein primary human lung epithelial and endothelial cells were cocultured at an air-liquid interface (ALI). To ensure that the cell culture mimics the physiological and functional characteristics of airway tissue, the model was characterized by evaluating several parameters such as cellular confluency, ciliation, tight junctions, mucus-layer formation, transepithelial electrical resistance, and barrier function through assaying fluorescein isothiocyanate-dextran permeability.
View Article and Find Full Text PDFComparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management.
Respir Res
January 2025
Department of Pulmonary, Allergy, and Critical Care Medicine, Chungnam National University School of Medicine, Daejeon, South Korea.
Background: Choosing effective devices (inhaled corticosteroid [ICS]-long-acting β2 agonist [LABA] combination inhalers) as maintenance treatment is critical for managing patients with asthma. We aimed to compare ICS/LABA combination efficacy, safety, and adherence across inhaler types and components in patients newly diagnosed with asthma.
Methods: Utilizing South Korea's National Health Insurance Service data, we conducted a population-based cohort study involving patients aged 18-80 years, newly diagnosed with asthma who received ICS/LABA combination therapy between January 2016 and December 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!